Lyell Immunopharma, Inc. (LYEL) vs Prelude Therapeutics Incorporated (PRLD)
A side-by-side comparison of Lyell Immunopharma, Inc. and Prelude Therapeutics Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LYEL
Lyell Immunopharma, Inc.
$8.61HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PRLD
Prelude Therapeutics Incorporated
$3.81HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — LYEL vs PRLD
growth of $100 · dividends reinvested · last 5yLYEL -97.3% (-51.5%/yr)PRLD -88.3% (-34.9%/yr)PRLD compounded faster over this window
LYEL PRLD
LYEL vs PRLD: by the numbers
- •PRLD is the larger company ($217M vs $211M market cap).
- •Both run net losses; PRLD's is the smaller (-269.75% vs -920285.19% net margin).
Metrics side by side
Valuation
| Metric | LYEL | PRLD |
|---|---|---|
| P/S ratio | 7814.17 | 9.67 |
| P/B ratio | 0.90 | 1.62 |
Profitability
| Metric | LYEL | PRLD |
|---|---|---|
| Gross margin | -31952.78% | 85.91% |
| Operating margin | -566038.89% | -861.33% |
| Net margin | -920285.19% | -269.75% |
| ROE | -106.27% | -45.23% |
| ROIC | -70.80% | -43.74% |
Growth (annualized)
| Metric | LYEL | PRLD |
|---|---|---|
| Revenue CAGR (5Y) | -68.32% | N/A |
| Total return CAGR (5Y) | -48.18% | -33.98% |
Frequently asked
- How have LYEL and PRLD total returns compared?
- Over the past 5 years, LYEL delivered -48.18% and PRLD delivered -33.98% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.